AAISG 2018 Annual Meeting
Didactic lectures allow the speakers to provide evidence based medical recommendations, updates and expert opinion in an efficient manner.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Allergy, Asthma & Immunology Society of Georgia (AAISG). The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is not supported by independent medical education grants.
Practicing allergists and allied health care providers in the field of allergy and immunology.
Upon completion of this activity, participants should be able to:
-Detect patients who could be appropriately challenged to food and proceed with desensitization, if appropriate.
-To deduce which biologic agents are appropriate for a particular patient.
Disclosure Policy and Disclosures As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All identified conflicts of interests have been resolved:
¨Mariana Castells, MD—Consultant for Sanofi, Performs contracted research for Genentech, Advisory Board member for Merck, Consultant for Lytix Biopharma, Consultant for Bentham Science
¨Phillip Lieberman, MD – Consultant and Speaker for Kaleo and Mylan
¨Brian Vickery, MD –Former Employee with ownership interest – divesting initiated March 2018 - Aimmune Therapeutics
The following have no relevant financial relationships to disclose:
Kathleen Sheerin, MD- AAISG President
Leslie Morris – Staff
Jeremiah Bivins, MD – Program Chair, Planner
Chloe Russo, MD
Desha Jordan, MD
Kristine Vanijcharoenkarn, MD
- 7.50 AMA PRA Category 1 Credit™
- 7.50 Attendance